Welcome to the Moderna fourth quarter 2024 conference call. At this time, all participants are in a listen-only mode. After ...
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Hosted on MSN20h
Moderna’s (NASDAQ:MRNA) Q4 Earnings Results: Revenue In Line With Expectations But Full-Year Sales Guidance Misses Expectations SignificantlyBiotechnology company Moderna (NASDAQ:MRNA) in Q4 CY2024, but sales fell by 65.6% year on year to $966 million. On the other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback